Skip to content

Kiniksa Pharmaceuticals International

US · KNSA #1938 by market cap Listed 2018
93.90 +0.36 +0.38%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 41 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.9 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
64.88% +1.92pp
Institutions
365 +41
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund44.17%
Hedge Fund14.99%
Individual/Insider4.06%
Public Company2.50%
Private Company1.65%
VC/PE Fund0.70%
Government Pension Fund0.64%
Insurance Company0.16%
Bank/Investment Bank0.11%
Other31.09%

Top holders as of 2026-09-30

FMR 9.53% · 7.49M sh
Rubric Capital Management LP 5.09% · 4.00M sh
BlackRock 3.75% · 2.94M sh
Baker Bros. Advisors LP 3.61% · 2.83M sh
Tang Capital Management, LLC 2.88% · 2.26M sh
Vanguard Portfolio Management, LLC 2.58% · 2.03M sh
Sanjiv Patel 2.11% · 1.65M sh
Vanguard Capital Management, LLC 1.82% · 1.43M sh
Robert Desnick 1.61% · 1.27M sh
Morgan Stanley 1.28% · 1.00M sh
Arrowstreet Capital, Limited Partnership 1.22% · 957.51K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 27 buys · 23 sells

NameRoleStake
Sanjiv Patel Chairperson & CEO 2.11%
John Paolini Chief Medical Officer 0.09%
Eben Tessari Consultant 0.03%
Michael Megna Chief Accounting Officer 0.04%
Richard Levy Independent Director 0.03%
Mark Ragosa Chief Financial Officer 0.03%
Kimberly Popovits Independent Director 0.02%
Ross Moat President, Executive VP, COO & Principal Operating Officer 0.02%
Tracey McCain Independent Director 0.02%
Thomas Malley Independent Director 0.02%
Felix Baker Lead Independent Director 0.02%
Julian Baker -- 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-08 Michael Megna Chief Accounting Officer Derivative Exercise and Sale -11,280 $17.76–98.54
2026-11-03 Sanjiv Patel Chairperson & CEO Automatic Disposition -5,537 $96.05
2026-11-03 Sanjiv Patel Chairperson & CEO Derivative Exercise and Sale -145,763 $17.92–96.05
2026-11-02 Sanjiv Patel Chairperson & CEO Open Market Disposition -171,257 $91.83–98.16
2026-11-02 Sanjiv Patel Chairperson & CEO Derivative Exercise and Sale -231,237 $8.83–93.53
2026-11-01 John Paolini Chief Medical Officer Derivative Exercise and Sale -96,000 $17.92–97.77
2026-11-01 Mark Ragosa Chief Financial Officer Derivative Exercise and Sale -36,783 $10.76–94.01
2026-11-01 Ross Moat President, Executive VP, COO & Principal Operating Officer Derivative Exercise and Sale -97,572 $10.76–96.03
2026-10-29 Sanjiv Patel Chairperson & CEO Intent to Sell (Form 144) -553,794 $93.12
2026-10-29 John Paolini Chief Medical Officer Intent to Sell (Form 144) -96,000 $93.02
2026-10-29 Michael Megna Chief Accounting Officer Automatic Disposition -16,365 $94.20–97.74
2026-10-29 Michael Megna Chief Accounting Officer Derivative Exercise and Sale -19,895 $10.76–94.20
2026-10-29 Ross Moat President, Executive VP, COO & Principal Operating Officer Automatic Disposition -6,013 $96.03–97.76
2026-09-02 Michael Megna Chief Accounting Officer Derivative Exercise and Sale -10,131 $79.28–80.30
2026-09-02 Michael Megna Chief Accounting Officer Intent to Sell (Form 144) -4,600 $80.30
2026-08-31 Sanjiv Patel Chairperson & CEO Derivative Exercise and Sale -15,144 $79.28
2026-08-31 Sanjiv Patel Chairperson & CEO Other Derivative Acquisition +30,050 --
2026-08-31 Sanjiv Patel Chairperson & CEO Other Derivative Acquisition +120,150 $79.28
2026-08-31 Sanjiv Patel Chairperson & CEO Derivative Exercise and Retained +16,174 --
2026-08-31 John Paolini Chief Medical Officer Derivative Exercise and Sale -4,029 $79.28

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Kiniksa Pharmaceuticals International discussion 0 comments

Add a comment